Cargando…
Development and characterization of liposomal formulation of bortezomib
Bortezomib is a proteasome inhibitor used for the treatment of multiple myeloma. The poor pharmacokinetic profile and off-target adverse effects provide a strong incentive to develop drug delivery systems for bortezomib. In the past, liposomal encapsulation has been proven to improve the therapeutic...
Autores principales: | Deshantri, Anil K., Metselaar, Josbert M., Zagkou, Stavroula, Storm, Gert, Mandhane, Sanjay N., Fens, Marcel H.A.M., Schiffelers, Raymond M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733293/ https://www.ncbi.nlm.nih.gov/pubmed/31517276 http://dx.doi.org/10.1016/j.ijpx.2019.100011 |
Ejemplares similares
-
Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma
por: Deshantri, Anil K., et al.
Publicado: (2020) -
Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma
por: Braham, Maaike VJ, et al.
Publicado: (2018) -
Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment
por: Alaarg, Amr, et al.
Publicado: (2016) -
Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis
por: Wong, Chee Wai, et al.
Publicado: (2018) -
A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy
por: Crielaard, Bart J, et al.
Publicado: (2011)